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ABSTRACT
THE NATURAL HISTORY OF THORACIC AORTIC ANEURYSM ASSOCIATED
WITH BICUSPID AORTIC VALVE
Thais Faggion Vinholo, Mohammad Zafar, Jinlin Wu, Dimitra Papanikolaou, Mohamed
Abdelbaky, Mahnoor Imran, Hesham Ellauzi, Joelle Buntin, Bulat Ziganshin, Sandeep
Mukherjee, John A. Elefteriades.
Aortic Institute, Yale University School of Medicine, New Haven, CT

Hypothesis: Thoracic aortic aneurysm (TAA) is a silent but virulent disease. Bicuspid
aortic valve (BAV) is the most common congenital heart disease. The association between
BAV and ascending TAA (ATAA) is well described. However, the guidelines for surgical
management to treat patients with thoracic aortic aneurysms associated with bicuspid aortic
valve (ATAA-BAV) remains controversial. We hypothesized that the surgical
management of patients with ATAA-BAV should not differ from the management of those
who have ATAA with a trileaflet aortic valve (TAV). Additionally, we suspected that
BAVs that are free of stenosis and regurgitation can be spared in the setting of ATAA
repair. In this study, we aimed to (1) characterize the natural behavior of BAV-ATAA, (2)
define surgical guidelines for elective intervention in patients with ATAA-BAV, and (3)
characterize the behavior of spared bicuspid aortic valves during ATAA resection.
Methods: A retrospective review of the Yale Aortic Institute database was done to identify
patients with ATAA-BAV. We calculated rate of growth, yearly rate of complications, 5year event-free survival through a Kaplan-Meier curve, as well as a logistic regression that
looked into risk of complications as a function of aortic size. Of these patients, the ones

whose valve was spared at the time of surgery were further analyzed. Postoperative and
preoperative echocardiograms were compared to determine changes in valve function of
this smaller cohort.
Results: We identified 514 patients with ATAA-BAV through data collection. The mean
growth rate of ATAA-BAV was 0.21 cm/year. The larger the aneurysm, the faster it grew.
There was a 13% yearly rate of rupture, dissection, and death in patients with an ATAA
diameter ≥ 6cm. These patients have a 13-fold increase risk of suffering an aortic
complication compared to patients with an aortic size of 4-4.5 cm (p<0.05). There was a
sharp increase in the probability of aortic complications including dissection, rupture, and
death at ATAA diameters of 5.0, 5.5, and 6.0 cm. Out of the 514 patients, did not have
their valve replaced. There was 100% echocardiogram follow-up for these 23 patients. The
average time between preoperative and postoperative echocardiograms was 4.50±4.09
years (0.19-15.63). Aortic stenosis or regurgitation changed from none to mild in 21.7% of
patients, with an average echocardiographic interval follow-up of 3.08 years, and from
none to severe in 2 (8.7%), with an interval of 11.7 years. One patient required reoperation,
including aortic valve replacement, during follow-up.
Conclusion: Prophylactic size-based surgery in BAV-ATAA patients can be considered at
5.0 cm at expert aortic centers as a means to afford protection from natural complication.
Non-expert center may wait for 5.5 cm. BAV free of aortic stenosis or insufficiency before
surgery and “healthy” appearing at surgery can safely be preserved.
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GLOSSARY OF ABBREVIATIONS
AI – Aortic Insufficiency
AS – Aortic Stenosis
ATAA – Ascending Thoracic Aortic Aneurysm
ATAA-BAV – Ascending Thoracic Aortic Aneurysm associated with BAV
ATAA-TAV – Ascending Thoracic Aortic Aneurysm associated with TAV
AVR – Aortic Valve Replacement
BAV – Bicuspid Aortic Valve
TAA – Thoracic Aortic Aneurysm
TAV – Trileaflet Aortic Valve
TAVR – Transcatheter Aortic Valve Replacement
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INTRODUCTION
Thoracic Aortic Aneurysm
Thoracic aortic aneurysm (TAA) is a silent but virulent disease. It affects roughly
1% of the general population, making aneurysm and dissection of the aorta a major cause
of death, accounting for 1-2% of deaths in Western Countries1. Most patients are
asymptomatic and incidentally diagnosed by chest x-ray, CT scan, or echocardiogram
acquired for alternative reasons2. In the absence of surgical intervention, the natural
behavior of TAA is progressive increase in size, often until a potentially-lethal
complication occurs, such as aortic dissection or rupture3. According to the Centers for
Disease Control and Prevention (CDC), aortic aneurysm is the 19th leading cause of death
overall and the 17th leading cause of death in individuals over 65 years of age, ranking well
above human immunodeficiency virus (HIV)4. Moreover, we suspect that even these
alarming numbers may be an underestimation. A Japanese study of postmortem CT scans
revealed that 7% of patients whose pre-hospital deaths were attributed to cardiopulmonary
arrest had actually suffered an acute aortic event5. This supports our suspicion and
highlights the need for further efforts to detect TAA prior to potentially lethal
complications.
The thoracic aorta resembles the shape of a candy cane. It is divided into ascending,
arch, and descending portions. The ascending segment begins at the aortic annulus and
ends at the brachiocephalic artery while the descending segment starts at the level of the
left subclavian artery (Figure 1). The aortic arch is found in between. The focus of this
thesis is on aneurysms involving the ascending portion of the aorta (ATAA).
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Figure 1. Anatomy of the aorta6.

Thoracic aortic aneurysm and dissection (TAAD) can be divided into two entities:
syndromic and non-syndromic. Syndromic TAAD involves other organ systems in addition
to the aorta, whereas non-syndromic TAAD is confined to the aorta. The involvement of
other organ systems can provide overt clinical signs of disease to alert the physician.
Syndromic patients suffer from systemic diseases such as Marfan syndrome, Loeyz-Dietz
syndrome, Ehlers-Danlos syndrome, arterial tortuosity syndrome, aneurysm-osteoarthriris
syndrome, and cutis laxa syndrome7. However, these syndromes only account for
approximately 5% of all TAADs, whereas familial and sporadic non-syndromic TAAD
account for 95% of TAAD7,8. Furthermore, the distinct cardiovascular, musculoskeletal,
and ocular phenotypic manifestations of syndromic TAAD may bring these patients to
medical attention earlier in their disease course, whereas the lack of overt clinical stigmata
in non-syndromic TAAD patients delays diagnosis, underlining the importance of finding
additional clues to detect TAA, especially in the non-syndromic category.
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In the search for further clues to help on the detection of TAA throughout the years,
TAA was proven to be associated with multiple comorbidities. A paradigm of “guilt by
association” was presented by Homick et al3 where a number of “guilty associates” that
are frequently accompanied by TAA were described including intracranial aneurysms,
abdominal aortic aneurysms, aortic arch anomalies, simple renal cysts, positive family
history of aortic disease, positive thumb-palm test, temporal arteritis, and bicuspid aortic
valve (BAV)3 (Figure 2). The most common associated aortic arch anomaly is the bovine
aortic arch, in which there is a common origin of the brachiocephalic and left common
carotid artery from the aortic arch. Any of these findings warrants further investigation for
the presence of TAA. Up to 84% of BAV patients are affected with ATAA9, 80-fold greater
than the general population10. The high prevalence of ATAA-BAV has driven scientific
efforts to understand the pathophysiology of this association.
Figure 2. Paradigm of “guilt by association” for detection of silent thoracic aortic aneurysms (reproduced
with permission from ref3).
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Natural History of TAA
The Aortic Institute at Yale has been internationally recognized for its investigative
efforts regarding the natural history of TAA since our original work on a cohort of 230
patients was published in 199711. Since then, we have been committed to describing the
behavior of TAA during its natural course in hopes of using this information to predict risk
of TAA complications, to guide surgical management, and ultimately to significantly
decrease the burden of this deadly disease.
Previous Studies
Height Index
Historically, absolute aortic diameter was used to predict future TAA behavior and
guide decision-making for surgical intervention. Subsequently, once patients body size was
shown to be associated with differing normal aortic sizes12, the aortic size index (ASI) was
introduced. The ASI is the aortic diameter divided by the body surface area (BSA); thus
both patient height and weight were incorporated into decision making13. However, our
group posited that height alone as an adjustment for normal aortic size and risk of TAA
complications might suffice (instead of BSA), as a person’s weight may vary throughout
an adult lifetime, but the aorta is unlikely to mirror that weight fluctuation. For instance, a
5 cm aneurysm may be tolerable for a 6’ tall person while it may present substantial danger
for someone who is 5’ tall. In a retrospective cohort study of 780 patients with ATAA, we
stratified annual risk of complications by a new measure, the aortic height index (AHI),
and demonstrated that AHI is not only equivalent but mildly superior as a predictor of
aortic complications compared to ASI14. The AHI is calculated by dividing the aortic
diameter by the patient’s height14. With this data we were able then to construct a
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nomogram to stratify patients as “low risk”, “moderate risk”, “high risk”, and “severe risk”
as a function of aortic diameter in relation to their height (Figure 3)14. Although this
nomogram is a highly useful guide for clinical decision-making for prophylactic aortic
aneurysm repair, it makes no distinction between patients with different aortic valve
morphology (BAV vs. trileaflet aortic valve (TAV)).
Figure 3. Risk of aortic event (dissection, rupture, and death) in patients with ATAA as a function of aortic
diameter and height14

Bicuspid Aortic Valve
The aortic valve is normally composed of three leaflets, making it a trileaflet valve.
However, failure of leaflet separation during embryogenesis may lead to an aortic valve
with only two distinct leaflets, rendering it a bicuspid aortic valve (BAV)15. BAV was first
described by Leonardo da Vinci over 400 years ago16. Since that time, it has drawn
significant attention for its major impact on society. For example, BAV is the most
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common congenital cardiac disorder and afflicts 1-2% of the general population17 with a
male/female ratio of 2:118.
The clinical presentation of BAV is remarkably heterogenous10. Age at diagnosis
ranges from neonates19 to the elderly20. BAV can be detected incidentally by auscultation
during physical exam or by advanced imaging such as echocardiography. Alternatively,
BAV may be detected in a symptomatic patient, as BAV is associated with early-onset
aortic insufficiency (AI), early-onset aortic stenosis (AS), and higher rates of bacterial
endocarditis18. These findings can lead to a rapid decline in BAV function21. BAV has been
identified as an underlying factor for as many as 50% of isolated stenotic aortic valves
meeting requirements for surgery22. The high prevalence of this abnormal valve
morphology, combined with its associated comorbidities, has driven an incredible effort
from the scientific community to understand this phenomenon.
Familial occurrence of BAV is common. Approximately 9-15% of first-degree
relatives of patients with BAV also have BAV21,23,24. To date, no single gene has been
unequivocally and generally associated with BAV. Still, the familial pattern observed
likely suggests a multifactorial genetic mechanism9. Secondly, it is noteworthy to
recognize that BAV is not always an independent phenomenon. BAV is often seen in
concurrence with other cardiovascular conditions including but not limited to coarctation
of the aorta, Turner syndrome, and Loeys-Dietz syndrome9.
BAV has been linked to aortic dissection and vasculopathies including ascending
aortic dilation and aneurysm formation. As mentioned previously, 84% of BAV patients
are affected with ATAA, 80-fold higher than the general population10. While these
numbers draw attention, they still may not fully capture the true number of affected
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patients, given that we may miss individuals who remain asymptomatic for the majority of
their lives.
ATAA Association with BAV
Historically, the association between ATAA and BAV has been explained by two
different schools of thought: the hemodynamic and genetic theories. Understanding the
root behind this association is important due to its important clinical implications.
Hemodynamic Theory
This theory alleges that the formation of aneurysms is due to the turbulent flow
caused by the abnormal BAV morphology. According to Sievers and colleagues, there are
three major types of BAV morphology: type 0, type 1, and type 2, with type 1 being the
most common (75% of clinical cases)25. Although these are often grouped together, it has
been demonstrated that the fusion pattern may determine the aortic wall shear stress
distribution throughout the aorta and consequently determine aortopathy remodeling9. The
classification is determined by the pattern of commissural fusion (Figure 4).
Figure 4. BAV phenotype morphology schematic presentation25.
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Genetic Theory
This theory supports the notion that there is a strong genetic component in the
development of ATAA in patients with BAV. The discovery of familial aggregation of
AAA by Tilson at Yale in 198426 ultimately triggered a search for genetic factors
contributing to the development of TAA in the late 1990s27,28.
Our group publishes annual updates reviewing the genes that have been associated
with TAA and dissection (TAAD) in the Yale journal AORTA. In a recent review, we
specifically described genes that have been associated with both ATAA and BAV29. Our
understanding of the genetics of ATAA-BAV continues to evolve every year. Recent
significant findings have enhanced our understanding of the pathogenesis of ATAA-BAV.
Gould et al, with the intent of identifying genes playing a role in the pathogenesis of nonsyndromic ATAA-BAV, performed whole-exome and targeted sequencing on 736
individuals with ATAA-BAV and 376 controls. In 1.77% of the affected individuals
(13/736), a new heterozygous mutation in the ROBO4 gene was identified, including 2
variants that segregated with disease among 2 affected families30. ROBO4 is markedly
expressed in endothelial cells and plays a role in endothelial barrier function. In this study,
ROBO4 expression was found to be diminished in the resected aorta of an affected
individual with ATAA. To further test their hypothesis that ROBO4 variants lead to
disruption of endothelial performance at a cellular level, thus altering vascular
permeability, the authors cultured human aortic endothelial cells and either silenced
ROBO4 or expressed ROBO4 variants. They confirmed that ROBO4 abnormalities did
indeed induce endothelial barrier dysfunction. Lastly, the authors created homozygous
ROBO4 knockout mice and a knock-in mouse with a ROBO4 splice donor site mutation;
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the affected mice presented with a mix of aortic valve dysfunction (BAV and/or aortic
regurgitation or stenosis) and ATAA, confirming their suspicion that a heterozygous
mutation in ROBO4 can lead to a non-syndromic presentation of ATAA-BAV30.
It is well documented that there is an increased risk for TAA among individuals
with Turner Syndrome (TS), although the precise etiology has thus far remained elusive.
Corbitt and colleagues shed light on this subject by demonstrating that TS individuals with
deleterious mutations in TIMP3 are significantly more likely to suffer from BAV and TAA
than TS patients without TIMP3 variants. Furthermore, they found that having
hemizygosity for TIMP1, which is functionally redundant to TIMP3, along with a TIMP3
variant, synergistically increased the risk for BAV and TAA31.
To date, 37 genes have been associated with TAAD. We estimated that at least 30%
of patients with familial and sporadic non-syndromic TAAD harbor variations in these 37
genes. Variations in 13 of these 37 genes have also been associated with BAV (ACTA2,
FBN2, FLNA, LOX, MAT2A, NOTCH1, ROBO4, SMAD3, SMAD6, TIMP3, TIMP1,
TGFB2, TGFBR1, TGFBR2)29. Most of these genes are involved in determining the
structure and maintenance of the aortic wall and its contained vascular smooth muscle cells
(VSMC)32. The increasing number of genes discovered every year has led us to believe
that ATAA is primarily a genetic disease, which suggests that ATAA-BAV may be no
different.
Certain genetic patients may develop acute aortic events at a smaller aortic
diameter. Hence, supporters of this theory consider the risk of acute aortic complications
to be higher in patients harboring these mutations and therefore apply more aggressive
management.
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Most authorities give credence to both hemodynamic and genetic contributions
ATAA-BAV patients.
Imaging Modalities
The biggest challenge in the realm of TAA remains unsolved: its diagnosis. Ideally,
patients with ATAA-BAV must be captured while they are still asymptomatic - that is,
before they develop an acute ATAA complication (rupture, dissection, or death).
TAA can be detected through the following imaging modalities: CXR,
echocardiography (transthoracic and transesophageal), computed tomography (CT) scan,
and magnetic resonance imaging (MRI). Fluorodeoxyglucose-Positron Emission
Tomography (FDG-PET)/CT imaging, a vascular metabolic imaging technique pioneered
by Sakalihasan and colleagues from Liege, is also emerging as a method to monitor aortic
aneurysm disease progression and to predict the risk of adverse aortic events based on
intensity of FDG uptake by inflammatory cells33. Although screening programs and criteria
are well established for other types of aneurysms, there are no clinical criteria in place for
patients with ATAA.
There exists no ‘gold-standard’ imaging modality for screening and monitoring
TAAs, with each method having its own limitations and advantages. Echocardiography is
most useful for visualizing the aortic root, while CT and MRI are more crucial for the
remaining segments of the aorta (mid ascending, arch, and descending aorta). The use of
echocardiography supplemented by CT or MRI allows for a comprehensive assessment of
the aorta34. Despite certain inherent limitations, TTE is the recommended imaging modality
for patients with ATAA-BAV9.
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Radiographic screening of aneurysms is extremely valuable and addresses the most
important factor guiding the decision to intervene electively: TAA size. However, imaging
alone does not suffice. We cannot image the entire general population, where detection of
asymptomatic TAA is paramount. However, negative imaging may lead to missed
aneurysms that are genetically programmed to occur but have not yet reached a detectable
size. Moreover, there are times when negative events might occur without the aorta having
achieved a significant enlargement, especially in the setting of pathogenic TAAD-causing
genetic mutations. This emphasizes the urgent need for biomarkers for TAAs, and better
screening tools for non-syndromic TAD such as in patients with ATAA-BAV. The purpose
of this study is to understand the behavior of ATAA-BAV.
Surgical Intervention Guidelines
Although ATAA is a potentially deadly disease, surgical repair restores a patient’s
life expectancy to normal35. The clinical decision in favor of surgery is made when the risk
of an adverse event supersedes the risks imposed by ATAA repair surgery. Thus, one of
the most important decisions for health care providers involving patients with ATAA-BAV
is the timing of surgery. Given that open cardiac surgery does not come without risk, it is
important to consider when the benefits of surgery outweigh its potential harm. We hope
that a better understanding of the natural behavior of ATAA-BAV will inform us when to
intervene surgically.
Most recent guidelines for prophylactic aortic repair surgery in patients with a TAV
recommend intervention at an aortic diameter of 5.0 cm. However, surgical management
for ATAA-BAV remains controversial. Multiple major international societies have created
diverging guidelines for managing patients with ATAA-BAV. These recommendations
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vary from aggressive approaches suggesting ATAA-BAV management be the same as for
Marfan and other connective tissue disorders, to more conservative measures.
Consequently, diverging guidelines have paradoxically raised more questions than
answers.
The American College of Cardiology/American Heart Association (ACC/AHA) in
2010 recommended ATAA replacement at a 5.0 cm diameter cutoff for patients free of
valve disfunction2. Subsequently, the same group released revised guidelines in 2014
recommending intervention at ATAA size of 5.5 cm36. In 2016, a clarification statement
was released by the ACC/AHA on the management of ATAA-BAV, recommending
surgical intervention at a 5.0 cm aortic diameter37. The change in recommendation within
a short period of time by the group sheds light on the fact that comprehensive knowledge
and prediction of ATAA-BAV remains elusive and lacks clear supporting evidence.
Recently, our principal investigator (J.A.E.) and other experts in the field published
a clarification statement regarding the ideal time for patients with ATAA-BAV to undergo
operative intervention. However, the authors admit that literature describing the long-term
events of patients with ATAA-BAV is lacking9. Guidelines have changed over recent
years, reflecting the lack of consensus due to insufficient understanding of the natural
history of ATAA-BAV.
Sparing the bicuspid aortic valve during aneurysmectomy
Similar to the management of ATAA-BAV, another controversy regarding the
management of BAV still exists. While current literature has focused on the efficacy of
BAV repair, valve replacement, or reimplantation of the BAV (the David procedure), we
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decided to investigate the behavior of completely spared, untouched valves, during ATAA
repair.
There is vast literature regarding the David operation, first described in 1989 by
David et al., when this procedure was performed in patients with Marfan’s syndrome and
a trileaflet aortic valve38. Since then, this procedure, involving aortic root replacement with
reimplantation of the aortic valve, has been extended to patients with BAV39. It is important
to highlight the distinction between the David operation, where the aortic root is replaced
and native aortic valve is re-implanted, and our patient cohort in whom the ascending aorta
was replaced but the aortic valve and aortic root were left untouched.
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STATEMENT OF PURPOSE AND SPECIFIC AIMS
The purpose of the study at hand is to provide information on the long-term
complications of ATAA-BAV and to inform future surgical recommendations for patients
with BAV. There is significant heterogeneity in BAV associated aortopathy, often
necessitating case-by-case decision-making regarding surgical intervention. The present
study comprises a large cohort of patients who have been followed both clinically and
radiographically until and after surgery.
Aim 1: To characterize the natural behavior of ascending thoracic aortic aneurysm
associated with bicuspid aortic valve;
Aim 2: To define surgical guidelines for elective intervention in patients with ascending
thoracic aortic aneurysm associated with bicuspid aortic valve;
Aim 3: To characterize the behavior of the spared bicuspid aortic valve during ascending
thoracic aortic aneurysmectomy.
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MATERIALS AND METHODS
This investigation was approved by the Human Investigation Committee of the
Yale University School of Medicine.
Patient Selection
The investigative efforts of the Aortic Institute at Yale-New Haven Hospital have
accrued 3,914 current or former patients with thoracic aortic disease (ascending and
descending) as part of our database. This database was queried to find patients with an
ascending aortic dimension of ≥ 3.5 cm during their first encounter at the Institute, and the
concomitant presence of a BAV. The morphology of the aortic valve was confirmed either
through echocardiographic imaging preoperatively or through direct observation
intraoperatively or both. 514 patients met our inclusion criteria, forming our study group
of ATAA-BAV. Patients who had undergone prior aortic valve replacement (AVR) or
ATAA surgical repair were excluded from the study. Although the threshold of 3.5 cm
approached the lower normal limit of an aneurysmal dimension, the intent of this study was
to capture ATAA at its early stage in order to observe growth in a comprehensive manner
over time. For the purpose of this study, the “ascending” aorta is defined as the segment
from the sinotubular junction aortic annulus to the innominate artery. We call the portion
between the aortic annulus and the sinotubular junction as the “aortic root”.
Of the patients fulfilling the criteria for the overarching natural history study
(N=514), a subset of patients had their BAV spared during the ATAA repair, forming
another separate study group. Our policy was to replace all BAVs with any significant
abnormality (aortic stenosis or insufficiency) observed through TEE or by direct visual
inspection that suggested that the BAV would not function adequately for many years we
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replaced any BAV that was significantly abnormal during TEE or direct inspection during
ATAA repair. ATAA-BAV patients that were found intraoperatively to have a functional
BAV had their valve spared, forming a subset of patients. From among the initial 514
patients, 491 had their aortic valve replaced or repaired, leaving 23 patients with preserved
BAVs who form the subgroup for this part of the study.
Data collection and processing
A thorough hospital chart review, including both paper and electronic records, was
done for the study group. During this review, clinical, surgical, radiologic, demographic,
and risk factor data were collected. Marfan syndrome and other connective tissue diagnoses
were applied when either proven through genetic testing or by convincing clinical stigmata
as evaluated by the senior author and primary investigator (J.A.E.). A positive family
history of TAA was indicated when a patient’s relative was diagnosed with TAA or aortic
dissection through an imaging study, intraoperative observation, or autopsy. When patients
reported sudden death in a family member, they were identified under the “possible” family
history category.
Long-term survival follow-up was done in accordance with the previously
described Yale Aortic Institute method - including online database interrogation, hospital
EMR interrogation (clinical and mortality), referring doctor follow-up, as well as online
obituary search40. The last date of proven clinical interaction was considered the end of the
follow-up period. Through this method, we were also able to determine whether or not the
patients had a TAA associated complication. The list of complications included type A
dissection, rupture, or death. A TAA associated complication and surgical intervention
were considered an end point follow up in our study.
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In order to assess and follow up on the BAV performance of the patients with BAV
spared, we measured function before, during, and after surgery via echocardiography for
these 23 patients. The severity of AS and/or AI were classified as either non/trace, mild,
moderate, or severe.
ATAA Measurement
Aortic dimensions were manually measured by our primary investigator (J.A.E.)
using one or more of the following imaging modalities: computed tomography (CT) scan,
transthoracic echocardiogram (TTE), or magnetic resonance imaging (MRI). Radiologic
reports from the Yale Radiology Department were also taken into consideration. When
there was a major discrepancy between the two reads, we would decide on the final
dimension through consensus during a group lab meeting with the participation of multiple
investigators including T.F.V. When faced with a measurement discrepancy between
different imaging modalities, the highest measurement was chosen. Serial aortic
measurements were carefully made in the same plane and anatomical level in sequential
scans. The maximal ATAA-BAV dimension was the largest measurement made prior to
the study end point (ATAA-BAV complication, operation, or end of follow-up).
We defined a patient as having a bovine aortic arch when the union of the
innominate and left common carotid arteries was observed above the aortic arch41 through
preoperative imaging or through direct observation intraoperatively.
Statistical analysis
Statistical analysis was performed using R 3.5.2 (R foundation for Statistical
Computing, Vienna, Austria) and Excel (Windows Excel 2016, Microsoft, Redmond, WA,
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USA). Means and standard deviations (SDs) were reported for continuous variables and
frequencies with percentages for categorical variables. Student t-test and Wilcoxon rank
sum test were done for continuous and categorical variables, respectively. Multivariable
logistic regression was performed to evaluate the association of aortic size with overall risk
for ATAA-BAV complication (aortic dissection, aortic rupture, and death), adjusting for
sex and age. These variables were chosen through a univariable analysis. Aortic size was
stratified into 6 different groups: 3.5-3.9, 4.0-4.4, 4.5-4.9, 5.0-5.4, 5.5-5.9, ≥6 cm. This
stratification was done based on the measurement distribution to permit meaningful
interpretation with an adequate number of observations within each group. Evaluation of
5-year event-free survival was done via Kaplan-Meier analysis.
We used an instrumental variable approach that was previously validated by our
group to estimate growth rates42. In essence, this approach was designed to diminish
inherent errors associated with measuring and comparing TAA dimensions42. Patient
characteristics including age, gender, Marfan syndrome/connective tissue disorder,
presence of family history, and bovine aortic arch configuration were considered in the
analysis to assess their impact on the growth rate.
Statistical significance was determined at a p-value of <0.05. (Statistics for the
natural history of ATAA-BAV were done by the author J.W.).
All patient characteristics whose BAV were spared were tested for statistically
significant association with change in BAV function. Fisher’s exact probability test was
used for binary variables and two-sample t test was used for continuous variables (these
statistics were performed by the author T.F.V.).
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RESULTS
ATAA-BAV Natural History
This section focuses on the natural behavior of ATAA-BAV over a period of time.
Patient characteristics are outlined in Table 1. The majority of patients were men (n=395,
76.7%). Median age was 55.1±13.7 years. Only 2.3% of patients had Marfan’s or another
connective tissue disorder and 78/514 (15.2%) had proven positive family history of aortic
disease.
Table 1. Baseline patient characteristics.
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The ATAA-BAV maximal size distribution is shown in Figure 5. The majority of
patients (34.82%) had a maximal aortic size ranging between 5.0 to 5.4 cm and only 7.19%
of patients had an aortic size ≥6cm.
Figure 5. Maximal ascending aortic dimension distribution before a study endpoint (aortic complication –
dissection, rupture, or death – or surgical intervention).

As depicted in Figure 6, the mean growth rate of ATAA-BAV was estimated to
be 0.21±0.04 cm/year. There was a positive correlation between increasing aneurysm size
and speed of growth: the larger the aneurysm, the faster it grew. In approximation, while a
4 cm aortic aneurysm grew at a rate of 0.16 cm/year, a 7 cm aortic aneurysm grew at a rate
of 0.28 cm/year.
Figure 6. Average annual growth rate of the ATAA-BAV based on initial aneurysm size.
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The average yearly risk of ATAA-BAV complications (dissection, rupture, and
death) for the 6 stratified aortic size groups (3.5-3.9, 4-4.4, 4.5-4.9, 5-5.4, 5.5-5.9, ≥6cm)
is depicted in Figure 7. The number above each histogram portrays the percentage of
patients at risk of each complication per year. Patients with larger aortic aneurysms were
subject to consistently higher yearly complication risks. An ATAA diameter ≥ 6cm was
associated with a 13% yearly risk of rupture, dissection, and death compared with 4.9% in
a 5-5.4 cm aortic size.
Figure 7. Yearly risk of ATAA-BAV complications (dissection, rupture, death, dissection/rupture,
dissection/rupture/death) at different aortic dimensions.

The probability of complications (rupture, dissection, and death) increased abruptly
at 3 hinge points: 5.0, 5.5, and 6.0 cm (Figure 8).
Multivariable regression analysis showed that patients with aneurysms ≥ 6cm have
a 13-fold increased risk of suffering an aortic complication (dissection or rupture)
compared to patients with an aortic size of 4.0-4.5 cm (p<0.05) (Table 2). Surgical
mortality in operated BAV-AATA patients was 4/425 (0.9%).
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Figure 8. Estimated probability of ATAA-BAV complications (dissection/rupture/death) by aneurysm size.

Table 2. Multivariable logistic regression of ATAA-BAV complication.
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Figure 9 illustrates the 5-year complication-free survival for ATAA-BAV as a
function of aortic size. Higher ATAA size was associated with decreased survival.
Figure 9. Kaplan-Meier curves for free of Event Free Survival (including dissection, rupture, death).
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Spared BAV
This section focuses on the patients who had their BAV spared during
aneurysmectomy surgery. These results have been published in the Journal of Cardiac
Surgery43. Patient characteristics are described in Table 3. Of the patient population
(n=23), 12 were male and 11 were female. The mean age was 62.0±11.8 years (39.0 –
81.2). No patients had Marfan or Ehlers Danlos syndrome. Both preoperative and
postoperative echocardiogram evaluations regarding BAV function were retrieved for all
patients. The mean aortic root dimensions were 3.52 cm pre-operatively and 3.67 cm postoperatively.
Table 3. Patient characteristics.

BAV Function
Pre-operatively, 22 patients had none or trace AS while 1 had mild. 15 patients had
none or trace AI, 7 had mild, and 1 had moderate. Post-operatively, 7 patients had an
increase in severity of either AS (Figure 10) and AI (Figure 11), or both. The overall mean
duration of echocardiography follow-up was 4.50±4.09 years (0.19-15.63). The mean
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number of years between pre-operative and post-operative echocardiograms for patients
who had an increase in AS or AI from none to mild and none to moderate/severe were
3.08±1.52 years (1.26 – 4.96) and 11.70±1.78 years (10.45 – 12.96), respectively, and for
those whose BAV function was unchanged were 3.85±4.10 (0.19-15.63). Additionally,
there were three patients whose AI went from mild pre-operatively to none post operatively
with an echo interval time average of 4.86±4.07 (0.47 – 8.53).
Figure 10. Change in aortic stenosis from preoperative (Pre-Op) echocardiogram to postoperative (Post-Op).
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Figure 11. Change in aortic valve insufficiency from preoperative (Pre-Op) echocardiogram to postoperative
(Post-Op).
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Reason for no AVR
One patient out of the studied cohort was adamant about having his valve spared.
Three patients had coronary artery bypass graft (CABG) done concurrently with the
ascending aortic aneurysm repair and the intention was to avoid adding to the complexity
of the surgery with superfluous AVR. Regardless of these factors, all patients did not
undergo AVR because their BAV was found to be in good condition, with no or almost no
calcification, and overall normal function on echo, with the senior author (J.A.E) judging
that the valve would last many years. Direct visual inspection and supplementary
intraoperative TEE evaluation of the aortic valve were used to make this determination.
We did not preserve valves that manifested thickening, fenestrations, or calcifications. Of
note, the one patient who had moderate AI pre-operatively presented with only minimal AI
when evaluated through transesophageal echocardiography intraoperatively.
Reoperation
One patient underwent a reoperation, which was accomplished safely. This patient
had an increase in AI severity (from none to severe) and underwent AVR. This patient had
undergone CABGx3, performed concurrently during the first surgery with the ascending
aortic aneurysm repair.
Change in BAV Function and Patient Characteristics
Associations between relevant risk factors and change in BAV function were tested
for statistical significance. No statistically significant association was demonstrated (Table
4).
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Table 4. Risk factors and change in bicuspid aortic valve function association.
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DISCUSSION
TAAs are known to be silent (most commonly causing no symptoms) and
continually grow toward the point at which dissection or rupture can occur. Rupture and
dissection, when they occur, can be lethal. However, if patients are identified, followed,
and treated with appropriate prophylactic surgical intervention, life expectancy can
essentially be restored to normal once the operation is complete. ATAA-BAV has a high
prevalence and continues to present a burden to the general population. Although this
association has been long established, the guidelines for surgical intervention are not clear
and supporting evidence remains elusive. In the present study, we report the natural history
data from a group of 514 patients with ATAA-BAV. We found that the ATAA in this group
of patients grows at 0.21 cm/year. Despite the growth rate being almost twice as fast as our
previous findings for all-inclusive ATAA (0.14cm/year)14, the risk of complications
adjusted for aortic size was comparable between both groups. In other words, although
ATAA-BAV may grow faster they do not seem to be more virulent than ATAA-TAV.
Hinge points
Figure 8 illustrates the increasing probability of ATAA-BAV complications
(dissection, rupture, and death) with increasing aortic size. There are three points where
the risk of complications increases significantly: 5, 5.5, and 6cm – the “hinge points”.
These were similar to the ones identified for all-inclusive patients with ATAA (5.25 and
5.75 cm)14. The comparable probability of aortic events between overall TAA and ATAABAV may suggest that the threshold for surgical repair of ATAA-BAV should not differ
from that of TAV-ATAA. Prophylactic size-based surgery in ATAA-BAV patients can be
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considered at 5.0 cm at expert aortic centers as a means to afford protection from natural
complications. Non-expert centers may wait for 5.5 cm.
Sparing BAV valve during ATAA surgical repair
The present study also supports applying surgical judgment regarding potential
concomitant replacement of a BAV at the time of ATAA replacement. Valves with good
function, free of significant AS or AI, and free of calcification at surgical inspection, can
safely be spared with expectation of continued good, long-term function.
Risk of AS or AI
Less than half of the patients experienced an increase in AS or AI over time (7/23, 30.4%).
Of those patients, 2 had an increase in severity of AS only, 4 of AI only, and 1 of both
(Figure 10, 11). Three patients had a decrease in severity of AI from mild to none (Figure
11).
Patients with increase in Aortic Stenosis or Aortic Insufficiency
Of the cohort of patients who had post-operative echos (n=23), 10 had changes in their
BAV function. However, of this group, only 7 had an increase in aortic stenosis or aortic
insufficiency. Most of them, 5 out of 7, had an increase in aortic stenosis or regurgitation
from none to mild. The remaining 2 patients had an increase from none to moderate or
severe.
Patient 1 did not have aortic stenosis or insufficiency pre-operatively. However, 12.96
years later, his echo revealed moderate aortic stenosis, while insufficiency progressed from
none to mild during the interval.
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Although patient 2’s echo showed continued freedom from stenosis, a worsening degree
of regurgitation, from none to severe, was observed. However, this patient’s surgery was
for a concomitant CABGx3. The complexity of the surgery, above and beyond a
straightforward ascending aneurysm repair played a role in deciding whether the valve
should or should not be spared. This is the only patient who required reoperation.
Thus, the only advent of severe bicuspid aortic valve disease in long-term follow-up in this
study (one patient) occurred under special circumstances: a patient undergoing extensive
associated CABG.
Limitations
The retrospective and single center nature of this study is a limitation. We recognize that
the cohort of patients for the assessment of the natural history of ATAA-BAV is from a
referral aortic center. This introduces a possible selection bias and may not precisely reflect
ATAA-BAV natural behavior in the general population. The group of patients who had
their valve spared during aneurysm repair is small. However, we are looking at a specific
subgroup among a very active aneurysm and bicuspid valve team’s cases.
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FUTURE DIRECTIONS
BAV Morphology
ATAA-BAV has been described with three different morphologies: supracoronary,
tubular, and marfanoid (Figure 12)9. The supracoronary type is the most common and has
been addressed as more “malignant” and to have a quicker progression of aortopathy.
Unfortunately, we did not differentiate the patients in this study into subgroups according
to their aortopathy morphology. We plan to categorize each patient in our larger cohort in
order to potentially guide management to each individual adjusting for ATAA morphology.
Further research on aortopathy phenotype can possibly increase the understanding of
ATAA-BAV pathophysiology.
Figure 12. ATAA-BAV morphology distribution (Yale Aortic Institute unpublished data).
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Genetics
Our understanding of the pathogenesis of TAAD is in constant evolution. The
advancement of genetic analysis techniques enables rapid progress in the genetic and
molecular understanding of TAA. As genome sequencing costs decrease, we anticipate
accelerating progress. With our greater understanding of the genetics of individuals
affected with TAAD and their specific genetic mutations, we can provide personalized
aortic care, tailoring surgical recommendations for each patient depending on the
individual mutation. Because most families, despite having multiple affected members
with TAAD, do not have any of the known aortopathy genes, we expect to discover many
new genes in the foreseeable future and thereby enhance our genetic dictionary.
Furthermore, it is important to remind ourselves that every disease-causing mutation starts
out as a variant of unknown significance (VUS). Only later does more data accumulate to
secure the status as a disease-causing mutation.
Although we value our clinical and surgical efforts to understand ATAA-BAV
behavior, we still believe that it is genetics that will enable individualized care for these
patients. Since 2012, we have been ordering genetic screening by way of Whole Exome
Sequencing (WES) on nearly all patients presenting to the Yale Aortic Institute. WES
encompasses DNA sequencing of all coding regions (exons) of a genome and provides the
following benefits: (1) it is comprehensive, including (but not limited to) testing all the 30plus TAAD genes that have been identified to date (all in a single test done in one
laboratory); (2) data can be reanalyzed retrospectively because the entire exome is
sequenced, permitting testing of new disease-causing genes as they are discovered; (3) it is
usually more affordable and efficient than testing individually for specific genes and
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syndromes in various laboratories; and (4) it provides genome-wide data that can be
‘mined’ for new mutations44. The fact that the genes identified to date only account for
approximately 30% of aortic diseases in non-syndromic TAAD patients leads us to believe
that there are many more genes yet to be discovered45.
The information gleaned from WES becomes very valuable for family members of
the proband. Once an individual is found to have a specific mutation, we look for that
specific mutation using the less complex and cheaper ‘single-site’ Sanger Sequencing
method in their family members46. In this technique, sequencing is targeted to the gene
already shown to harbor an anomalous variant in the proband genome46. This way, instead
of going through the “whole genetic alphabet” we can focus on the more likely culprit
“letter” found in the proband.
RNA Signature
In addition to looking at the genetic profile of our patients (DNA), we are currently
working on identifying RNA expression patterns in peripheral blood that could be
diagnostic for TAA, including ATAA-BAV. Success in such work would constitute a
major advancement in the clinical care of the general population. Our previous study
identified a distinct gene expression, ‘RNA Signature’, in peripheral blood that was able
successfully to identify whether a patient had an aneurysm, with over 80% overall
accuracy47. Furthermore, this RNA Signature test was able to differentiate very accurately
between ascending vs. descending aortic aneurysm, and between familial or sporadic
TAA47. We are currently completing a follow-up study aimed at validating our previous
findings and developing a clinically useful simple blood test that can not only detect and
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monitor aneurysm disease, but also biologically predict the risk of catastrophic aortic
events based on the differential expression of aneurysm related RNAs.
Transcatheter Aortic Valve Replacement
In an era where endovascular approaches are taking center stage, we must consider
the role transcatheter aortic valve replacement (TAVR) will play for BAV patients. The
Placement of Aortic Transcatheter Valves PARTNER 3 Clinical trial showed that patients
at low surgical risk undergoing a TAVR had non-inferior outcomes compared to surgical
aortic valve replacement (SAVR)48. Patients with BAV morphology were excluded from
the study group due to concern for the valve anatomy (i.e. non-circular annulus)49.
However, since then, multiple centers representing the cardiovascular community have
enrolled in an ongoing clinical trial to evaluate clinical outcomes of patients undergoing
TAVR-BAV50. Although this is not yet approved by the FDA, it is important for us to
consider what this will mean for patients with ATAA-BAV. This trial has focused on
patients affected by BAV but has not considered patients that also suffer from vasculopathy
linked to its valve morphology. Although endovascular techniques are already extant for
the descending portion of TAA, we suspect that repair for ATAA will not be readily
available in the near future, thus posing an even more challenging question of whether
patients with stenotic BAV in conjunction with ATAA should be considered for TAVR.
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CONCLUSION
This body of work allows us to arrive at the following conclusions:
1. ATAA-BAV grows at 0.21cm/year.
2. The natural risk of aortic complications (rupture and/or dissection) rises with
increase in aortic size with three discriminative hinge points: 5, 5.5, and 6 cm.
3. Prophylactic size-based surgery in ATAA-BAV patients, just like TAV-ATAA,
can be considered at 5.0 cm at expert aortic centers in order to avoid adverse aortic
events.
4. BAV with good function, free of significant AS or AI, and free of calcification at
surgical inspection, can safely be spared with the expectation of continued good
long-term function.
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